Johnson & Johnson (JNJ) has been the center of attention in the bio-tech market recently. Despite some stock slide, fundamentals are promising and a market correction is predicted. The company has been active with acquisitions like the $1B purchase of Yellow Jersey and the $1.25B purchase of experimental skin disorder drug. The firm faced criticism with allegations over 'fraudulent' bankruptcies’ and has proposed a whopping $6.5B settlement for talc cancer lawsuits. Still, its drug for depression and insomnia showed promising results in late-stage studies. Reflecting this mixed bag, Goldman Sachs reinstated J&J at neutral. In spite of legal issues, J&J was named among the most innovative companies and the world's most admired company. The firm’s acquisition of Proteologix for $850M and the extension of VERMOX® donation program through 2030 signify their resolve to innovate and give back. Even though the report of four patient deaths in an early-stage prostate cancer trial by J&J raised concerns, the company's commitment to fighting cancer, as shown in their acquisition of Shockwave Medical for $13.1B is commendable. Their healthcare innovations and intention to develop new AI applications for surgery, alongside Nvidia, cements their place as a front runner in the bio-tech market.
Johnson Johnson JNJ News Analytics from Thu, 20 Jul 2023 07:00:00 GMT to Thu, 30 May 2024 21:45:14 GMT -
Rating -2
- Innovation 8
- Information 7
- Rumor 4
